共 50 条
Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
被引:9
|作者:
Bryce, Adam S.
[1
,2
]
Dreyer, Stephan B.
[1
,2
]
Froeling, Fieke E. M.
[1
,3
,4
]
Chang, David K.
[1
,2
]
机构:
[1] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Sch Canc Sci, Switchback Rd, Bearsden G61 1BD, Scotland
[2] Glasgow Royal Infirm, West Scotland Pancreat Unit, 84 Castle St, Glasgow G4 0SF, Lanark, Scotland
[3] Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland
[4] Beatson West Scotland Canc Ctr, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland
来源:
关键词:
pancreatic ductal adenocarcinoma;
PDAC;
cancer associated fibroblast;
tumour microenvironment;
immunotherapy;
pancreatic cancer;
IDENTIFY MOLECULAR SUBTYPES;
HEDGEHOG PATHWAY INHIBITOR;
STELLATE CELLS;
TUMOR-STROMA;
IMMUNE SUPPRESSION;
ONCOGENIC KRAS;
BETA-CATENIN;
PHASE-II;
FIBROSIS;
MYOFIBROBLASTS;
D O I:
10.3390/cancers14215302
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterised by a stubbornly low 5-year survival which is essentially unchanged in the past 5 decades. Despite recent advances in chemotherapy and surgical outcomes, progress continues to lag behind that of other cancers. The PDAC microenvironment is characterised by a dense, fibrotic stroma of which cancer-associated fibroblasts (CAFs) are key players. CAFs and fibrosis were initially thought to be uniformly tumour-promoting, however this doctrine is now being challenged by a wealth of evidence demonstrating CAF phenotypic and functional heterogeneity. Recent technological advances have allowed for the molecular profiling of the PDAC tumour microenvironment at exceptional detail, and these technologies are being leveraged at pace to improve our understanding of this previously elusive cell population. In this review we discuss CAF heterogeneity and recent developments in CAF biology. We explore the complex relationship between CAFs and other cell types within the PDAC microenvironment. We discuss the potential for therapeutic targeting of CAFs, and we finally provide an overview of future directions for the field and the possibility of improving outcomes for patients with this devastating disease.
引用
收藏
页数:25
相关论文